Airsonett® Air4 is a medical device for effective home treatment of allergic asthma and eczema. The patented TLA technology provides 99.5% clean air in the breathing zone. Your airways and immune system can rest and recuperate when you sleep, and you wake up rested, ready for a new day.
Why Air4? It’s effective
Dr. Robert Boyle
St. Mary’s Hospital, London
“Airsonett Air4 reduces airway inflammation and thereby relieves symptoms, without the need for drugs or burdensome changes to the home environment.”
Read the latest news on Airsonett and see where you can meet us at tradeshows or demo events.
Airsonett Air4 provides a clinical improvement in Quality of Life within 3 months of treatment
January 11, 2019
An independent time to onset (TTO) study, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of Respiratory and Allergology, University Hospital Lund, Sweden), concludes that Nocturnal treatment with TLA provided a statistically significant and clinically relevant improvement in total Quality of Life score (AQLQ) within 3 months in patients with poorly controlled asthma. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.
“Allergen elimination is one of the cornerstones in asthma management. The rapid response to treatment is important from a clinical perspective allowing firm conclusions already after a short test period. This is highly appreciated” says Leif Bjermer, Professor Department of Respiratory and Allergology, University Hospital Lund, Sweden.
“We had previous indications that the clinical effects of the TLA technology were evident within 3-6 months. Having this now documented at three months as well as one month for sleep is fantastic” says Anders Due-Boje, CEO Airsonett AB.
For the full article in Respiratory Medicine, please visit:
About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed,and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
Airsonett AIR4 maintains good control of severe allergic asthma after withdrawal of omalizumab July 11, 2018
An independent study by Professor C. Wang concludes in the title of the study “A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma(SAA) after withdrawal of Omalizumab therapy”. The study will be published in a poster session at ERS on Asthma Management session on Sunday 16 September 2018.
“We are naturally very positive to these interesting data and look forward to feedback from the health care sector” says Anders Due-Boje, CEO at Airsonett AB.
Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other airborne irritants from the patient’s breathing zone during the nightly sleep.
Airsonett AB announces that the company has appointed Anders Due-Boje as its new CEO July 4, 2018
Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR-4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other airborne irritants from the patient’s breathing zone during the nightly sleep.
Anders Due-Boje took up his position as CEO in 18 June. Anders has experience in developing both SME’s and larger corporations on a global level in the Medical Device and Information Industry and he has a strong sales and marketing focus. Anders has had leading positions within various companies, among others Neoventa Medical, GN Netcom och Motorola.
“Anders has more than 25 years’ international experience from management positions in the Medical Device and Information industry and he will be able to assist the company to take the next step in a successful development” says Magnus Lundberg, Chairman at Airsonett AB.